Scripps Translational Science Institute
Both efforts are employing popular consumer wearables and health trackers to spot potential cases of COVID-19 or other viral diseases as they begin.
By combining prior CDC data with heart rate and sleep measurements, Scripps developed a new disease tracking model that they say could deliver speedy and accurate estimates.
New data published yesterday in the journal Hypertension offers another proof of concept for how device and mobile-driven remote monitoring can help care teams manage the conditions of a large patient population.
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception.
Patients at increased risk for atrial fibrillation wearing iRhythm’s Zio patch — a continuous ECG monitoring wearable — were more likely to have their atrial fibrillation diagnosed early and receive subsequent preventive care, according to one-year results from a late-breaking study presented at the American College of Cardiology’s annual meeting.
News broke earlier this week that Scripps Translational Science Institute’s Wired For Health study showed the digital health monitoring used in the randomized control trial of 160 patients had no impact on outcomes or the cost of care during the first six months.
The results are in for the Scripps Translational Science Institute’s Wired For Health study, and there’s no sugar-coating it: they’re disappointing for those working in digital health.
The Scripps Translational Science Institute is working with Aetna and Johnson & Johnson to launch a trial that will test iRhythm's Zio Patch and the Amiigo activity tracker as possible new ways to screen at-risk populations for atrial fibrillation.
Mountain View, California-based Amiigo, which makes an activity tracker that raised $580,000 on Indiegogo in 2013, has teamed up with online patient community platform Alliance Health to launch a new study looking at the combined effect of wearables and peer support on heart failure patients.
Aliso Viego, California-based Sentrian, the remote patient monitoring company formerly known as Jointly Health, will work with Scripps Translational Science Institute to study its technology on 2,000 patients with COPD.